Merit Medical Systems, Inc.

NasdaqGS:MMSI Stock Report

Market Cap: US$4.6b

Merit Medical Systems Valuation

Is MMSI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of MMSI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: MMSI ($77.18) is trading below our estimate of future cash flow value ($83.21)

Significantly Below Future Cash Flow Value: MMSI is trading below future cash flow value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MMSI?

Key metric: As MMSI is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for MMSI. This is calculated by dividing MMSI's market cap by their current earnings.
What is MMSI's PE Ratio?
PE Ratio35.4x
EarningsUS$128.49m
Market CapUS$4.59b

Price to Earnings Ratio vs Peers

How does MMSI's PE Ratio compare to its peers?

The above table shows the PE ratio for MMSI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average19.7x
LNTH Lantheus Holdings
20.7x14.94%US$4.8b
HAE Haemonetics
16.8x13.74%US$2.9b
ALGN Align Technology
32.8x15.68%US$13.6b
SOLV Solventum
8.3x8.53%US$12.9b
MMSI Merit Medical Systems
35.7x12.94%US$4.6b

Price-To-Earnings vs Peers: MMSI is expensive based on its Price-To-Earnings Ratio (35.7x) compared to the peer average (19.7x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does MMSI's PE Ratio compare vs other companies in the US Medical Equipment Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
EMBC Embecta
4.4x5.68%US$607.60m
MHUA.F Meihua International Medical Technologies
0.8xn/aUS$7.70m
ADVB Advanced Biomed
1.4xn/aUS$5.54m
ARTH.Q Arch Therapeutics
n/an/aUS$4.00
No more companies available in this PE range
MMSI 35.4xIndustry Avg. 30.9xNo. of Companies8PE020406080100+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: MMSI is expensive based on its Price-To-Earnings Ratio (35.7x) compared to the US Medical Equipment industry average (30.9x).

Price to Earnings Ratio vs Fair Ratio

What is MMSI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MMSI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio35.4x
Fair PE Ratio25.3x

Price-To-Earnings vs Fair Ratio: MMSI is expensive based on its Price-To-Earnings Ratio (35.7x) compared to the estimated Fair Price-To-Earnings Ratio (25.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MMSI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$76.50
US$102.00
+33.33%
9.95%US$122.00US$78.00n/a11
Feb ’27US$81.09
US$104.00
+28.25%
8.73%US$122.00US$90.00n/a10
Jan ’27US$88.14
US$103.60
+17.54%
8.45%US$122.00US$90.00n/a10
Dec ’26US$86.39
US$102.50
+18.65%
8.87%US$122.00US$90.00n/a10
Nov ’26US$87.54
US$104.40
+19.26%
7.70%US$122.00US$90.00n/a10
Oct ’26US$82.08
US$103.10
+25.61%
7.72%US$122.00US$90.00n/a10
Sep ’26US$90.54
US$103.55
+14.36%
7.45%US$122.00US$90.00n/a11
Aug ’26US$84.78
US$104.36
+23.10%
7.74%US$122.00US$90.00n/a11
Jul ’26US$93.98
US$108.55
+15.50%
4.93%US$122.00US$100.00n/a11
Jun ’26US$95.03
US$108.55
+14.22%
4.93%US$122.00US$100.00n/a11
May ’26US$93.20
US$106.91
+14.71%
5.33%US$122.00US$100.00n/a11
Apr ’26US$105.45
US$118.36
+12.25%
4.03%US$128.00US$111.00n/a11
Mar ’26US$102.04
US$118.20
+15.84%
4.21%US$128.00US$111.00US$77.1810
Feb ’26US$108.88
US$118.80
+9.11%
3.87%US$128.00US$110.00US$81.0910
Jan ’26US$96.72
US$113.70
+17.56%
6.44%US$127.00US$103.00US$88.1410
Dec ’25US$103.90
US$110.50
+6.35%
6.60%US$125.00US$103.00US$86.3910
Nov ’25US$98.80
US$110.09
+11.43%
6.43%US$125.00US$103.00US$87.5411
Oct ’25US$97.61
US$107.91
+10.55%
8.52%US$125.00US$94.00US$82.0811
Sep ’25US$96.68
US$99.55
+2.96%
10.33%US$125.00US$85.00US$90.5411
Aug ’25US$84.12
US$96.36
+14.55%
11.38%US$125.00US$85.00US$84.7811
Jul ’25US$85.64
US$93.73
+9.44%
7.35%US$107.00US$85.00US$93.9811
Jun ’25US$81.15
US$92.70
+14.23%
8.23%US$107.00US$85.00US$95.0310
May ’25US$76.63
US$91.60
+19.54%
8.85%US$107.00US$80.00US$93.2011
Apr ’25US$75.13
US$94.22
+25.41%
9.69%US$112.00US$85.00US$105.459
Mar ’25US$76.26
US$94.22
+23.55%
9.69%US$112.00US$85.00US$102.049
US$102
Fair Value
25.0% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/02 22:46
End of Day Share Price 2026/03/02 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Merit Medical Systems, Inc. is covered by 22 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David RescottBaird
null nullBaird
Michael PetuskyBarrington Research Associates, Inc.